Biologic therapy and its effect on skeletal development in children with chronic inflammation

References

• Karlberg J, Jalil F, Lam B, Low L, Yeung CY. Linear growth retardation in relation to the three phases of growth. Eur. J. Clin. Nutr.48(Suppl. 1), S25–S43 (1994).
   PubMed Web of Science ®Google Scholar
• Goldenberg N, Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol. Metab. Clin. North Am.36(1), 37–55 (2007).
   PubMed Web of Science ®Google Scholar
• Bougneres P, Goffin V. The growth hormone receptor in growth. Endocrinol. Metab. Clin. North Am.36(1), 1–16 (2007).
   Google Scholar
• Isaksson OG, Jansson JO, Gause IA. Growth hormone stimulates longitudinal bone growth directly. Science216(4551), 1237–1239 (1982).
   PubMed Web of Science ®Google Scholar
• Green H, Morikawa M, Nixon T. A dual effector theory of growth-hormone action. Differentiation29(3), 195–198 (1985).
   PubMed Web of Science ®Google Scholar
• Zezulak KM, Green H. The generation of insulin-like growth factor-1 – sensitive cells by growth hormone action. Science233(4763), 551–553 (1986).
   PubMed Web of Science ®Google Scholar
• Perry RJ, Farquharson C, Ahmed SF. The role of sex steroids in controlling pubertal growth. Clin. Endocrinol. (Oxf.)68(1), 4–15 (2008).
   PubMed Web of Science ®Google Scholar
• Briard N, Guillaume V, Frachebois C et al. Endotoxin injection increases growth hormone and somatostatin secretion in sheep. Endocrinology139(6), 2662–2669 (1998).
   Google Scholar
• Daniel JA, Elsasser TH, Martinez A, Steele B, Whitlock BK, Sartin JL. Interleukin-1β and tumor necrosis factor-α mediation of endotoxin action on growth hormone. Am. J. Physiol. Endocrinol. Metab.289(4), E650–E657 (2005).
   Web of Science ®Google Scholar
• Gong FY, Deng JY, Shi YF. Stimulatory effect of Interleukin-1β on growth hormone gene expression and growth hormone release from rat GH3 cells. Neuroendocrinology81(4), 217–228 (2005).
   PubMed Web of Science ®Google Scholar
• Soto L, Martin AI, Millan S, Vara E, Lopez-Calderon A. Effects of endotoxin lipopolysaccharide administration on the somatotropic axis. J. Endocrinol.159(2), 239–246 (1998).
   PubMed Web of Science ®Google Scholar
• Wada Y, Sato M, Niimi M, Tamaki M, Ishida T, Takahara J. Inhibitory effects of interleukin-1 on growth hormone secretion in conscious male rats. Endocrinology136(9), 3936–3941 (1995).
   Google Scholar
• Peisen JN, McDonnell KJ, Mulroney SE, Lumpkin MD. Endotoxin-induced suppression of the somatotropic axis is mediated by interleukin-1 β and corticotropin-releasing factor in the juvenile rat. Endocrinology136(8), 3378–3390 (1995).
   Google Scholar
• Haedo MR, Gerez J, Fuertes M et al. Regulation of pituitary function by cytokines. Horm. Res.72(5), 266–274 (2009).
   Google Scholar
• Martensson K, Chrysis D, Savendahl L. Interleukin-1β and TNF-α act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J. Bone Miner. Res.19(11), 1805–1812 (2004).
   Google Scholar
• MacRae VE, Farquharson C, Ahmed SF. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol.189(2), 319–328 (2006).
   PubMed Web of Science ®Google Scholar
• MacRae VE, Wong SC, Smith W et al. Cytokine profiling and in vitro studies of murine bone growth using biological fluids from children with juvenile idiopathic arthritis. Clin. Endocrinol. (Oxf.)67(3), 442–448 (2007).
   Google Scholar
• Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev.208, 207–227 (2005).
   PubMed Web of Science ®Google Scholar
• Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol. Rev.208, 154–168 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn’s disease on bone metabolism in vitro: a role for interleukin-6. J. Bone Miner. Res.17(4), 695–702 (2002).
   Google Scholar
• Tatsumi S, Ishii K, Amizuka N et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab.5(6), 464–475 (2007).
   PubMed Web of Science ®Google Scholar
• Tan SD, Kuijpers-Jagtman AM, Semeins CM et al. Fluid shear stress inhibits TNFα-induced osteocyte apoptosis. J. Dent. Res.85(10), 905–909 (2006).
   PubMed Web of Science ®Google Scholar
• Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology94(3), 603–610 (1988).
   PubMed Web of Science ®Google Scholar
• Polk DB, Hattner JA, Kerner JA Jr. Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn’s disease. JPEN J. Parenter. Enteral. Nutr.16(6), 499–504 (1992).
   PubMed Web of Science ®Google Scholar
• Morin CL, Roulet M, Roy CC, Weber A. Continuous elemental enteral alimentation in children with Crohn’s disease and growth failure. Gastroenterology79(6), 1205–1210 (1980).
   PubMed Web of Science ®Google Scholar
• Wong SC, MacRae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J. Pediatr. Gastroenterol. Nutr.43(2), 144–155 (2006).
   PubMed Web of Science ®Google Scholar
• Zak M, Muller J, Karup PF. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm. Res.52(2), 80–85 (1999).
   PubMedGoogle Scholar
• Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Treatment of growth failure in juvenile chronic arthritis. Horm. Res.58(Suppl. 1), 28–32 (2002).
   PubMedGoogle Scholar
• Hankard R, Munck A, Navarro J. Nutrition and growth in cystic fibrosis. Horm. Res.58(Suppl. 1), 16–20 (2002).
   Google Scholar
• Lilleby V, Lien G, Frey FK, Haugen M, Flato B, Forre O. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum.52(7), 2051–2059 (2005).
   PubMedGoogle Scholar
• Kotaniemi A, Savolainen A, Kroger H, Kautiainen H, Isomaki H. Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand. J. Rheumatol.28(1), 19–26 (1999).
   PubMed Web of Science ®Google Scholar
• Leonard MB, Shults J, Wilson BA, Tershakovec AM, Zemel BS. Obesity during childhood and adolescence augments bone mass and bone dimensions. Am. J. Clin. Nutr.80(2), 514–523 (2004).
   PubMed Web of Science ®Google Scholar
• Nilsson O, Marino R, De Luca F, Phillip M, Baron J. Endocrine regulation of the growth plate. Horm. Res.64(4), 157–165 (2005).
   PubMedGoogle Scholar
• Petit MA, Beck TJ, Shults J, Zemel BS, Foster BJ, Leonard MB. Proximal femur bone geometry is appropriately adapted to lean mass in overweight children and adolescents. Bone36(3), 568–576 (2005).
   PubMed Web of Science ®Google Scholar
• Burnham JM, Shults J, Semeao E et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J. Bone Miner. Res.19(12), 1961–1968 (2004).
   PubMed Web of Science ®Google Scholar
• Daci E, van Cromphaut S, Bouillon R. Mechanisms influencing bone metabolism in chronic illness. Horm. Res.58(Suppl. 1), 44–51 (2002).
   PubMedGoogle Scholar
• Cezard JP, Touati G, Alberti C, Hugot JP, Brinon C, Czernichow P. Growth in paediatric Crohn’s disease. Horm. Res.58(Suppl. 1), 11–15 (2002).
   PubMedGoogle Scholar
• Haworth CS, Selby PL, Webb AK et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax59(7), 613–617 (2004).
   Google Scholar
• Aris RM, Stephens AR, Ontjes DA et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med.162(5), 1674–1678 (2000).
   PubMed Web of Science ®Google Scholar
• Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics118(1), 124–129 (2006).
   PubMed Web of Science ®Google Scholar
• Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.18(2), 165–173 (1994).
   PubMed Web of Science ®Google Scholar
• Buller HA. Growth in children with inflammatory bowel disease. Research and Clinical Forums22, 139–144 (2000).
   Google Scholar
• Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS. Growth, body composition, and nutritional status in children and adolescents with Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.31(1), 33–40 (2000).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm. Bowel Dis.12(8), 797–813 (2006).
   PubMed Web of Science ®Google Scholar
• Pappa HM, Gordon CM, Saslowsky TM et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics118(5), 1950–1961 (2006).
   PubMed Web of Science ®Google Scholar
• Sylvester FA. IBD and skeletal health: children are not small adults! Inflamm. Bowel Dis.11(11), 1020–1023 (2005).
   Google Scholar
• Issenman RM. Bone mineral metabolism in pediatric inflammatory bowel disease. Inflamm. Bowel Dis.5(3), 192–199 (1999).
   Google Scholar
• Sylvester FA, Wyzga N, Hyams JS et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm. Bowel Dis.13(1), 42–50 (2007).
   PubMed Web of Science ®Google Scholar
• Harpavat M, Greenspan SL, O’Brien C, Chang CC, Bowen A, Keljo DJ. Altered bone mass in children at diagnosis of Crohn disease: a pilot study. J. Pediatr. Gastroenterol. Nutr.40(3), 295–300 (2005).
   Google Scholar
• Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov.6(1), 75–92 (2007).
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin. Rheumatol.27(1), 67–76 (2008).
   PubMed Web of Science ®Google Scholar
• Diamanti A, Basso MS, Gambarara M et al. Positive impact of blocking tumor necrosis factor a on the nutritional status in pediatric Crohn’s disease patients. Int. J. Colorectal Dis.24(1), 19–25 (2009).
   PubMed Web of Science ®Google Scholar
• Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.42(1), 40–45 (2006).
   PubMed Web of Science ®Google Scholar
• Cezard JP, Nouaili N, Talbotec C et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric crohn disease. J. Pediatr. Gastroenterol. Nutr.36(5), 632–636 (2003).
   PubMed Web of Science ®Google Scholar
• Borrelli O, Bascietto C, Viola F et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig. Liver Dis.36(5), 342–347 (2004).
   PubMedGoogle Scholar
• Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm. Bowel Dis.13(4), 424–430 (2007).
   PubMed Web of Science ®Google Scholar
• Thayu M, Leonard MB, Hyams JS et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin. Gastroenterol. Hepatol.6(12), 1378–1384 (2008).
   PubMed Web of Science ®Google Scholar
• Pfefferkorn M, Burke G, Griffiths A et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J. Pediatr. Gastroenterol. Nutr.48(2), 168–174 (2009).
   PubMed Web of Science ®Google Scholar
• Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin. Exp. Rheumatol.21(6), 779–784 (2003).
   Google Scholar
• Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann. Rheum. Dis.65(8), 1044–1049 (2006).
   Google Scholar
• Vojvodich PF, Hansen JB, Andersson U, Savendahl L, Hagelberg S. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J. Rheumatol.34(12), 2481–2485 (2007).
   PubMed Web of Science ®Google Scholar
• Ryan BM, Russel MG, Schurgers L et al. Effect of antitumour necrosis factor-α therapy on bone turnover in patients with active Crohn’s disease: a prospective study. Aliment. Pharmacol. Ther.20(8), 851–857 (2004).
   PubMedGoogle Scholar
• Miheller P, Muzes G, Racz K et al. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm. Bowel Dis.13(11), 1379–1384 (2007).
   PubMed Web of Science ®Google Scholar
• Abreu MT, Geller JL, Vasiliauskas EA et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J. Clin. Gastroenterol.40(1), 55–63 (2006).
   PubMed Web of Science ®Google Scholar
• Franchimont N, Putzeys V, Collette J et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment. Pharmacol. Ther.20(6), 607–614 (2004).
   PubMed Web of Science ®Google Scholar